期刊文献+

脂蛋白(a)单克隆抗体制备与表位分析

Lp(a) monoclonal antibody development and epitope analysis
下载PDF
导出
摘要 目的:解决脂蛋白(a)抗体批间差大,以及试剂盒检测结果不一致的问题。方法:制备脂蛋白(a)单克隆抗体,筛选与Kringle IV-2无反应,且能自身配对的杂交瘤细胞株,并对抗体识别位点与检测特异性进行分析。结果:获得了一株识别Kringle IV-5的单抗,标记为LPa-3,该单抗能够实现自身配对,用LPa-3单抗作为包被抗体与标记抗体初步建立的夹心ELISA方法检测15份血清样品,检测结果与商品试剂盒具有较好的相关性:y=0.190 4 x-0.032 6,R2=0.922。结论:LPa-3单抗能实现自身配对,检测特异性好,是一种优良的体外诊断试剂盒原料,为胶乳增强免疫比浊试剂盒的开发奠定了基础。 Objective:Resolve the problem of Lp(a) antibody, such as the high variation between batches and can be affected by Kringle IV-2 polymorphism. Methods: Develop Lp(a) hybridomas and screen cell lines secreting antibodies matched itself and without reaction to Kringle IV-2. Antibody binding site and serum specificity were tested by indirect ELISA and sandwich ELISA, re- spectively. Results: Obtained a candidate hybridoma named LPa-3. LPa-3 monoclonal antibody recognize the Kringle IV-5 domain of Lp ( a), and matched with itself in sandwich ELISA for serum Lp(a) detection. The comparative assay with 15 fresh serum samples in- dicates that LPa-3 sandwich ELISA with high correlation to a commercial immunoturbidimetric assay kit. The correlation equation and coefficient were y = 0. 190 4 x - O. 032 6 and R2 = O. 922, respectively. Conclusion: LPa-3 antibody, matched itself and unaffected by Kringle IV-2 polymorphism, will be an excellent candidate for the development of a latex-enhanced immunoturbidimetric assay method.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2014年第4期505-507,519,共4页 Chinese Journal of Immunology
基金 北京博士后科研活动经费资助(No.2012ZZ-69)
关键词 脂蛋白(a) KRINGLE Ⅳ-2 单克隆抗体 抗体配对 Lp(a) Kringle IV-2 Monoclonal antibody Matched antibody
  • 相关文献

参考文献14

  • 1张捷,乔蕊.脂蛋白(a)的研究进展[J].检验医学,2012,27(1):1-3. 被引量:16
  • 2McLean JW, Tomlinson JW,Kuang WJ, et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen [ J ]. Na- ture, 1987, 330(6144) :132-137.
  • 3Koschinsky ML. Novel insights into Lp(a) physiology and patho- genicity: more questions than answers [ J ]. Cardiovasc Hematol Disord Drug Targets,2006, 6(4) : 267-278.
  • 4Van der Hoek YY, Wittekoek ME, Beisiegel U, et al. The apoli- poprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably sized isoforms[ J]. Hum Mol Gen- et, 1993, 2(4) :361-366.
  • 5Lackner C, Cohen JC, Hobbs HH. Molecular definition of the ex-treme size polymorphism in apolipoprotein(a) [ J]. Hum Mol Gen- et, 1993, 2(7): 933-940.
  • 6Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentra- tion and the risk of coronary heart disease, stroke, and nonvascular mortality[J]. JAMA, 2009, 302(4) : 412-423.
  • 7Seanu AM,Lawn RM, Berg K. Lipoprotein (a) and atheroselerosis [J]. AnnlntemMed,1991,115(3): 209-218.
  • 8Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associ- ated with Lp(a) lipoprotein level and coronary disease[ J]. N En- gl J Med, 2009, 361(26): 2518-2528.
  • 9汪俊军.脂蛋白(a)的检测与临床研究新进展[J].临床检验杂志,2010,28(6):449-452. 被引量:5
  • 10李守霞,杨建英,郭丽丽,刘波,史广生.两种方法检测Lp(a)的结果比对及偏差评估[J].国际检验医学杂志,2008,29(2):122-123. 被引量:5

二级参考文献16

  • 1汪俊军,顾振华,张春妮,范乐明.脂蛋白(a)氧化和自身免疫与动脉粥样硬化的关系[J].医学研究生学报,2005,18(8):740-742. 被引量:22
  • 2Berg K. A new serum type system in man -the Lp system [ J]. Acta Pathol Microbiol Scand, 1963, 59:369-382.
  • 3Koschinsky ML. Novel insights into Lp (a) physiology and pathogenicity : more questions than answers [ J ]. Cardiovasc Hematol Disord Drug Targets, 2006, 6 (4) :267-278.
  • 4Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al.Genetically elevated lipoprotein (a) and increased risk of myocardial infarction [ J]. JAMA, 2009, 301 (22) :2331-2339.
  • 5Striver CR, Beaudet AL, Sly WS, et al. The metabolic and molecular bases of inherited disease [ M ]. 8th ed. New York: McGraw-Hill, 2001 : 2753-2787.
  • 6Matthews KA, Sowers MF, Derby CA, et al. Ethnic differences in cardiovascular risk factor burden among middle-aged women: study of women's health across the nation (SWAN) [ J ]. Am Heart J, 2005, 149 (6) :1066-1073.
  • 7Tate JR,Rifai N,Berg K, et al. International federation of clinical chemistry standardization project for the measurement of lipoprotein (a). Phase I. Evaluation of the analytical performance of lipoprotein (a) assay systems and commercial calibrators [ J ]. Clin Chem, 1998,44 (8 Pt 1 ) : 1629-1640.
  • 8Tate JR, Berg K, Couderc R, et al. International federation of clinical chemistry and laboratory medicine (IFCC) standardization project for the measurement of hpoprotein (a). Phase 2 : selection and properties of a proposed secondary reference material for lipoprotein (a) [ J ]. Clin Chem Lab Med, 1999, 37 (10) :949-958.
  • 9Marcovina SM, Koschinsky ML, Albers JJ, et al. Report of the national heart, lung, and blood institute workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions[J]. Clin Chem, 2003, 49(11 ) :1785-1796.
  • 10National Institutes of Health. National cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) [ S]. 02-5215, NIH, 2002.

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部